Life-Saving Medications Made Affordable: GST Cut on Key Cancer Drugs

The CBIC has made a concerted effort to enhance the facility for healthcare services, with the action on the new amendments in GST rates which has been recommended by the GST Council. A notable change is the reduction of the GST rate to 5% on three vital cancer drugs: T-DXd, Osimertinib and Durvalumab. These medications are useful in several cancer types and  they often influence patients’ quality of life. Reduction of the GST rate on these essential medicines is meant to reduce the financial burden on affected patients and their families so that a cure for such life threatening diseases could be realized with ease. This is in line with government priorities for improving health care, which most importantly means that individuals with cancer should also get their treatment without making a hole in their pockets. The reduction in GST rates is one of the tribute features that pare down the Council’s competency in the manufacturing of the GST policies, which directly impact the lives of people. This is a major step as we go forward in dealing with issues posed by health costs as a society, to cancer victims and to the survivability of the disease.

Overview of the GST Changes

Reduction of GST on Cancer Drugs

The CBIC has made a good start in terms of attempting to finesse accessibility to healthcare services through tread adjustments to standard GST rates, as first proposed by the GST Council. A notable change is the reduction of the GST rate to 5% on three vital cancer drugs: T-DXd, Osimertinib, and Durvalumab. These medicines are essential to the management of multiple kinds of cancer and can really change the life of a patient.

Why This Change Matters

The reduction in GST rates on cancer drugs is significant for several reasons:

1. Affordability: 

Reduction of the GST to 5% has a considerable effect on the availability of these drugs. Cancer treatments are very costly and any form of cutting the cost can help the patient and families to some extent.

2. Accessibility: 

With low taxes, producers can lower their prices, which can increase accessibility of these medicines in some regions of India, for example, in rural areas where the healthcare infrastructure is weak.

3. Encouragement for Research and Development: 

It has thus identified this policy change may lead to pharmaceutical companies increasing their research and development expenditure for new cancer medicines since the market for these products will be more friendly.

Understanding GST and Its Implications

• What is GST?

The Goods and Services Tax (GST) is an indirect tax reform in India where implementation of GST has been done on the 1 st of July, 2017. It supplanted several indirect taxes which were hitherto administered by the center as well as the states. The overarching goal of GST is to eliminate duplicate taxes and set up a unified system that improves compliance, non-occurrence of tax avoidance and is beneficial for businesses.

• The Role of the GST Council

That is why the decisions made by the GST Council in the current fiscal framework of India remain acute. The council consists of both central and state government members and in this council, there are periodic meetings where Perfecting and changing of GST rates, compliance and other related tax policies are made. Such current recommendations as the cancer drugs as a matter were apt to point that the council of the Presidency had concentrated on the core aspects of the requirements for the medical care within the tax framework.

Also Read: 54th GST Council Meeting Highlights: Updates, and Outcome

Impact on the Pharmaceutical Industry

Short-Term Effects

In the short-run, the scaled down of the GST rates on cancer drugs will increase the demand of the goods. Consumers who once could not afford these drugs may now afford treatment regimens that they once could not imagine. This could lead to an increase of the sales for the pharmaceutical firms and consequently have an added positive implication of lifting up the stock prices of the pharmaceutical firms.

Long-Term Considerations

In the long term, this policy shift may lead to:

• Increased Competition: 

This means that the prices might reduce due to competition from many firms due to the new technologies. This may potentially contribute to radical cost slashing and diversification of reels in the drugs’ formulation.

• Sustainability of Drug Availability:

The government may have to consider the effects that this aspect of tax reduction has on the longer continuity of drugs in the nation. Essentially, when the number goes up considerably it is important that the units remain consistent with the demand rate.

Broader Implications for Healthcare in India

1. Impact on Healthcare Costs

The recent cut in the GST on cancer drugs is only one part of the picture when it comes to the Indian healthcare costs. Other domains may also need to be defined, for example, hospital services and diagnostics to ensure a patient can receive the support which is needed. To further improve the favourableness of healthcare costs, the government could think over assessing GST rates on different services relating to healthcare.

2. Creating Awareness and Informing Patients

When these changes take place it behooves the healthcare delivery system to make sure that patients understand their choices. Paternalistic prescriptions on the news pricing structures for these cancer drugs and their probable effects has to be explained to the patients.

Also Read: GST and the Healthcare Sector

Navigating the Future of GST in India

1. Potential Future Changes

And as the field of healthcare and pharmaceuticals has shifted in years and in the future, there is barely any doubt that GST has remained a debatable topic. The GST Council may decide in the future to fix a new approach that would affect other essential segments such as medical devices, hospital services, and even products for health improvement. Sustaining a close eye on such changes will therefore be crucial for health care players.

2. Engagement of Stakeholders

The intergovernmental collaboration and patient-popular pharmaceutical companies, healthcare delivery shall be instrumental in creating a ‘Good Stewardship Tax.’ It is therefore important to have continuous tax consultative forums and feedback so that tax policies and approaches are in touch with the people.

Also Read: The Future of Tax and GST in India

Government Initiative to Enhance Healthcare Affordability

The announcement of a GST cut on essential cancer medications is a landmark initiative aimed at addressing one of the most pressing challenges in healthcare. Very expensive treatment that is normally attributed to cancer patients. The rationale behind this policy change is well understood with complexities involved in handling financial aspects of individual patients, as well as, the drive to being society inclined amidst implementing health reforms. It goes beyond being a disease because it becomes a financial disaster to the families of the patient and even the patient themselves. Expenses mount up rapidly, especially because the patient may have several rounds of chemotherapy, radiation, and surgery, and different additional supportive care drugs needed during the course of therapy. Thus, many of these patients have to make life wrenching decisions on whether to go through with the treatments or not due to financial restraints. 

The Economic Context

The reduction of the GST on cancer drugs is even sadder, especially seeing that the costs of healthcare services are escalating across the world. Current statistics show that the incidence of cancer continues to rise, particularly in LMC countries, at which the families could barely afford bearing these expenses. The WHO global estimate of cancer mortality stands at 9.6 million deaths for 2020 underlining WHO, and thus the need to address cancer care holistically. There are usually factors in regard to price determination for up pharmaceuticals that include cost of research and development as well as cost of production and distribution. In cases where cancer medication has extremely high-profit margins, the prices skyrocket hence becoming a preserve of a few. Other than slashing the aforementioned monetary cost, the government has lowered the GST and in so doing, makes it clear that its focus is on making the prices more affordable for its population and this message is directed towards the pharmaceutical giants.

Positive Outcomes of the GST Reduction

1. Broader Impact on Society:

Increasing healthcare costs make financial toxicity meaning the costs that patients and their families bear part of normal oncology practice parlance. This can be a great deal in alleviating the GST which in turn will result in reduced social costs, such as fewer bankruptcies and lower levels of outstanding medical bills.

2. Strengthening Patient Advocacy:

The same has also been supported by many patient support groups and non-profit organizations that have been advocating for right policies of health care to be passed. These organizations have a critical function as watchdogs and advocates in getting the word out of treatment accessibility problems as well as patient support during their cure.

3. Increased Research Funding:

If the patient debt tends to go down, the people can afford to contribute to the clinical trials and cancers. This will also in its own way advance the pace of finding new forms of therapy and treatment to build an environment of development and innovation for the general betterment of patient care.

4. Partnerships Between Government and Private Sector:

The reduction of the GST is not strictly a governmental matter, but it also requires partnerships with players in the pharmaceutical industry. Rather, this partnership may create new approaches to pricing and programs including the patient assistance programs which directly target one ultimate goal – no patient should be barred from taking needed medication due to financial reasons.

Addressing Challenges Beyond GST

Although cutting the GST is a good first step, there are problems. Making these medications as readily accessible for families in remote cautiously remote areas as in the densely populated urban areas is essential. Vigorous efforts need to be exerted at enhancing the system for the operations of logistics, supply chain, and healthcare delivery system. Also, the government as well as other stakeholders should ensure that insurance reforms that include all rounded insurance cover that include treatment of cancers are enhanced to ease any burden on patients.

• Public Awareness and Education: 

Another issue that will determine the success is the public’s awareness about available resources, including awareness created by this initiative. Finally, where drugs have been made cheaper, patients need to be aware of how to get these cheaper drugs and navigate through the complicated health care system for these benefits to capture them.

Conclusion 

The decrease in GST on several critical cancer treatments is a move to enhance an equitable health care system since cancer has a way of consuming the needs of the affected patients and their families. To ensure the changes are maintained and improved continuously, a model of healthcare access should be developed by all stakeholders; government, pharmaceutical industries, providers, and patient organization. We must insist on the further development of its policies which support the well-being of patients but do not lead to financial insecurity, to guarantee that everybody has the opportunity to afford necessary medicine. The fight against cancer favors no individual or country, when everybody can unite and join the fight; it should not be one that is fueled by individual financial capacity.

Also Listen: CaptainBiz | Making your business digital is the future

FAQ

1. What is the range of GST cut on cancer medications?

The so-called GST cut, which is used to characterize the change in the level of the Goods and Services Tax concerning essential cancer medication, is actually a process of lowering the cost of these medications for patients.

2. What led to the GST cut?

The cut was carried out to improve the availability of and access to cancer treatments that have become expensive due to increased healthcare costs to the detriment of patients.

3. Will all those cancer medications be brought under the reduced GST?

The GST reduction is usually applicable to vital cancer treatment drugs, as per the HS code, but the precise list of drugs qualifying for the reduction will be unveiled by the government.

4. Will the GST cut reduce the overall cost to healthcare overall?

Increased public access to affordable essential medicines which will translate to an overall cut on the overall healthcare costs to patients and, therefore, a reduction in the number of patients falling prey to ‘medical bill poverty’.

5. In what way can the reduction of GST for cancer drugs impact the result of clinical trials?

The proposed concept Act aims at decreasing co-payments for necessary medications; it may help increase the population’s involvement in clinical trials, since trials of experimental treatments can be afforded by people with lower costs of necessary medicines.

6. Is the GST cut change in policy permanent or just a policy change in a short term period?

Although the GST cut may be implemented as a permanent measure, it may be adjusted in future based on political, economical, or the conditions of healthcare systems.

7. How will the extent of the GST cut have been determined?

These might include whether or not patients are able to access medicines, changes in overall health-care costs, and patient health status and health professional responses.

8. Does the above GST cut relate to any special patient assistance programs?

Indeed, there are many healthcare organizations or pharmaceutical firms that have patient assistance programmes which aim at ensuring that patients obtain medications they need at considerably reduced or sometimes no charge at all.

9. In what way does the GST cut contribute to the broader health care policy, or reform, project?

The GST cut is to reduce the cost of medical services to consumers, signifies the government keen to solve problems in the health departments and work in favor of patients’ interests.

10. In what ways can patients push for other alterations to enhance the availability of cancer products?

To make further modifications patients have to come together in common support groups and organizations, approach the policymakers with their stories, use social media platforms to spread awareness about the existing difficulties faced while trying to gain access to cancer treatments and the medications.

Rutuja Khedekar Freelance Copywriter

Rutuja is a finance content writer with a post-graduate degree in M.Com., specializing in the field of finance. She possesses a comprehensive understanding of financial matters and is well-equipped to create high-quality financial content.

See Full Bio